ALG-3 Inhibitors
Chemical inhibitors of ALG-3 can modulate its activity through various signaling pathways by targeting key enzymes and kinases that are upstream or interconnected with the functional role of ALG-3. PD98059 and U0126, for instance, are selective inhibitors that target MEK1 and MEK2, which are integral to the MAPK/ERK pathway. These compounds prevent the activation of ERK2, a downstream target that ALG-3 interacts with when phosphorylated. By inhibiting this phosphorylation event, ALG-3's interaction with ERK2 is reduced, leading to a decrease in its functional activity. Similarly, SL327 operates by inhibiting MEK, thereby preventing ALG-3 from engaging with activated ERKs. SP600125, targeting JNK, and SB203580 as well as BIRB 0796, both targeting p38 MAP kinase, obstruct signaling pathways that could be related to ALG-3's activity. By inhibiting JNK and p38 MAP kinase, these inhibitors may reduce the phosphorylation of proteins that ALG-3 might interact with, hence decreasing ALG-3's activity.
In addition to MAPK pathway inhibitors, compounds such as LY294002 and Wortmannin target the PI3K/AKT pathway. By inhibiting PI3K, these compounds suppress AKT activation and its downstream signaling, which can lead to a reduction in ALG-3's activity if it is dependent on this particular signaling route. Rapamycin, an inhibitor of mTOR, further suppresses downstream signaling of the PI3K/AKT/mTOR pathway, which also can lead to a reduction in ALG-3's activity. PP2 and Dasatinib are broad-spectrum kinase inhibitors, with PP2 selectively targeting Src family tyrosine kinases and Dasatinib inhibiting a range of tyrosine kinases including Src family kinases. By disrupting the activity of these kinases, ALG-3's functional interactions within various signaling pathways are inhibited. Lastly, LFM-A13, a selective inhibitor of Bruton's tyrosine kinase (BTK), may influence ALG-3's activity by impairing signaling pathways in which BTK plays a role, thus impacting ALG-3's functional capacity. Each of these inhibitors works by impeding specific enzymes or kinases, which in turn can reduce the functional activity of ALG-3 by limiting its ability to interact with key signaling molecules.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is a selective and potent inhibitor of mitogen-activated protein kinase kinase (MEK), which is upstream of extracellular signal-regulated kinases (ERKs) in the MAPK/ERK pathway. ALG-3 is known to interact with ERK2, and by inhibiting MEK, PD98059 can prevent the activation of ERK2, thereby functionally inhibiting ALG-3 by preventing its interaction with phosphorylated ERK2. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is known to selectively inhibit MEK1 and MEK2, which are upstream regulators of ERKs in the MAPK pathway. By inhibiting these kinases, U0126 reduces the activation of ERKs, which in turn would inhibit the functional interaction of ALG-3 with its phosphorylated substrate, thereby decreasing ALG-3's activity. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK), which is part of the MAPK signaling pathways. Inhibition of JNK can decrease the crosstalk between JNK and ERK pathways, which may reduce the phosphorylation of downstream targets of ERK, indirectly inhibiting the functional activity of ALG-3 in cells. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a potent inhibitor of the phosphoinositide 3-kinases (PI3K), which are upstream of AKT signaling. PI3K inhibition can decrease AKT activation and subsequently its downstream signaling, which could inhibit the interaction of ALG-3 with other proteins in the PI3K/AKT pathway by reducing the pathway's overall activity. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is another potent inhibitor of PI3K. By inhibiting PI3K, wortmannin can suppress the PI3K/AKT pathway, potentially inhibiting downstream interactions of ALG-3 that are dependent on this pathway's signaling, resulting in a functional inhibition of ALG-3. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is an inhibitor of p38 MAP kinase, part of the MAPK signaling pathway. By inhibiting p38 MAP kinase, SB203580 could reduce the functional activity of ALG-3 if ALG-3's function is linked to the p38 MAPK pathway through downstream signaling interactions. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin is an inhibitor of mTOR, which is a key part of the PI3K/AKT/mTOR pathway. By inhibiting mTOR, rapamycin can suppress the downstream signaling of this pathway, which can indirectly inhibit the functional activity of ALG-3 by reducing the activation of pathway components that may interact with ALG-3. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $92.00 $223.00 | 30 | |
PP2 is a selective inhibitor of Src family tyrosine kinases. Src kinases can modulate various signaling pathways, including those in which ALG-3 may be involved. Inhibition of Src kinases by PP2 could thus impede the pathways and interactions necessary for ALG-3's functional activity. | ||||||
SL-327 | 305350-87-2 | sc-200685 sc-200685A | 1 mg 10 mg | $107.00 $332.00 | 7 | |
SL327 is an inhibitor of MEK, which is involved in the ERK/MAPK pathway. By inhibiting MEK, SL327 can prevent the phosphorylation and activation of ERKs, thereby potentially inhibiting the functional activity of ALG-3 that is dependent on its interaction with activated ERKs. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
Dasatinib is a broad-spectrum tyrosine kinase inhibitor with activity against Src family kinases and other kinases. By inhibiting these kinases, dasatinib can disrupt multiple signaling pathways, including those that may involve ALG-3, leading to functional inhibition of ALG-3's activity within those pathways. | ||||||